Kolkata, Feb 18: Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”), an innovation-led global life sciences company, today announced the launch of PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device. Featuring a patented 3-resistance system, the drug-free, handheld device is designed to support effective mucus clearance and improve breathing in patients suffering from COPD, asthma, and bronchiectasis.
More than 90 lakh patients in India live with chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and bronchiectasis. Chronic mucus hypersecretion remains a persistent challenge among these patients, often requiring daily airway clearance therapy. PEPAIR™ addresses this need by offering an accessible, non-pharmacological solution for routine respiratory care.
The device is being launched under an agreement with AeroDel Technology Innovations Pvt. Ltd., a medical device company focused on simplifying inhalation and pulmonary rehabilitation solutions. In a patient-centric move, Zydus has priced PEPAIR™ at an affordable Rs. 990 per unit to improve accessibility.
Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said,
“At Zydus, patient-centric innovation is about advancing healthcare in ways that make everyday care more accessible for patients. With PEPAIR™, India’s first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis. We look forward to expanding our efforts in advancing respiratory health through this launch.”
OPEP therapy uses a handheld, translucent device that creates controlled pressure and vibrations during exhalation. These oscillations help loosen mucus, open airways, and promote its clearance from the lungs. PEPAIR™ supports impaired mucociliary pathways, assists in removing airway obstruction, reduces cough, and enhances overall therapeutic response. While OPEP-based airway clearance is recommended in established clinical guidance, affordability constraints have limited access for many patients—an important gap PEPAIR™ aims to bridge.
Respiratory diseases in India are witnessing a sharp rise due to extreme and persistent air pollution, climate-driven changes in allergens and ozone levels, rapid urbanisation, and delayed diagnosis of chronic lung conditions. The launch of PEPAIR™ aligns with Zydus’ broader commitment to strengthening respiratory healthcare solutions in the country.
Zydus is among India’s leading respiratory care players, backed by a strong legacy in oral and inhalation therapies. The company leads the oral bronchodilator segment with Deriphyllin®, one of India’s most prescribed methylxanthines. Its inhalation portfolio spans Inhaled Corticosteroid (ICS) + Long-Acting Beta2-Agonist (LABA), LABA + Long-Acting Muscarinic Antagonist (LAMA), and Single Inhaler Triple Therapy (SITT). Zydus was the first to introduce LABA + LAMA with Forglyn® and pioneered SITT with Forglyn® Plus. The company further advanced innovation with once-daily triple therapies such as Odihale® G and Umiflo® Plus.
With PEPAIR™, Zydus reinforces its commitment to accessible innovation, expanding its respiratory portfolio with a practical, affordable, and drug-free solution aimed at improving quality of life for millions of patients across India.